Summary
Global Markets Direct’s, ‘Allergic Asthma - Pipeline Review, H1 2016’, provides an overview of the Allergic Asthma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Asthma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Allergic Asthma
- The report reviews pipeline therapeutics for Allergic Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Allergic Asthma therapeutics and enlists all their major and minor projects
- The report assesses Allergic Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Allergic Asthma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Allergic Asthma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
ALK-Abello A/S
Allergopharma GmbH & Co. KG
Amgen Inc.
Aquinox Pharmaceuticals Inc.
ASIT biotech s.a.
Aslan Pharmaceuticals Pte. Ltd.
Axikin Pharmaceuticals, Inc.
Baxalta Incorporated
Chiesi Farmaceutici SpA
Circassia Pharmaceuticals Plc
CSL Limited
Fountain Biopharma Inc.
GlaxoSmithKline Plc
Hydra Biosciences, Inc.
Infinity Pharmaceuticals, Inc.
Kineta, Inc.
Mabtech Limited
Marinomed Biotechnologie GmbH
Mycenax Biotech Inc.
NeoPharm Co., Ltd.
Oxagen Limited
Panacea Biotec Limited
Peptinnovate Limited
Pharmaxis Limited
Protectimmun GmbH
Stallergenes SAS
sterna biologicals Gmbh & Co KG
Swecure AB
The International Biotechnology Center (IBC) Generium
Verona Pharma Plc
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Allergic Asthma Overview 8
Therapeutics Development 9
Pipeline Products for Allergic Asthma - Overview 9
Pipeline Products for Allergic Asthma - Comparative Analysis 10
Allergic Asthma - Therapeutics under Development by Companies 11
Allergic Asthma - Therapeutics under Investigation by Universities/Institutes 13
Allergic Asthma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Allergic Asthma - Products under Development by Companies 17
Allergic Asthma - Products under Investigation by Universities/Institutes 20
Allergic Asthma - Companies Involved in Therapeutics Development 21
ALK-Abello A/S 21
Allergopharma GmbH & Co. KG 22
Amgen Inc. 23
Aquinox Pharmaceuticals Inc. 24
ASIT biotech s.a. 25
Aslan Pharmaceuticals Pte. Ltd. 26
Axikin Pharmaceuticals, Inc. 27
Baxalta Incorporated 28
Chiesi Farmaceutici SpA 29
Circassia Pharmaceuticals Plc 30
CSL Limited 31
Fountain Biopharma Inc. 32
GlaxoSmithKline Plc 33
Hydra Biosciences, Inc. 34
Infinity Pharmaceuticals, Inc. 35
Kineta, Inc. 36
Mabtech Limited 37
Marinomed Biotechnologie GmbH 38
Mycenax Biotech Inc. 39
NeoPharm Co., Ltd. 40
Oxagen Limited 41
Panacea Biotec Limited 42
Peptinnovate Limited 43
Pharmaxis Limited 44
Protectimmun GmbH 45
Stallergenes SAS 46
sterna biologicals Gmbh & Co KG 47
Swecure AB 48
The International Biotechnology Center (IBC) Generium 49
Verona Pharma Plc 50
Allergic Asthma - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Target 53
Assessment by Mechanism of Action 56
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
AcTMP-1 - Drug Profile 63
AMG-282 - Drug Profile 64
AQX-1125 - Drug Profile 65
Arabinogalactan - Drug Profile 68
ASLAN-004 - Drug Profile 69
ASM-8 - Drug Profile 70
AXP-1275 - Drug Profile 72
beta-escin - Drug Profile 73
CHF-6001 - Drug Profile 74
CSL-311 - Drug Profile 76
dalazatide - Drug Profile 77
Drug to Inhibit PI3 Kinase Delta for Asthma - Drug Profile 79
duvelisib - Drug Profile 80
EP-67 - Drug Profile 83
FB-825 - Drug Profile 84
GNR-044 - Drug Profile 85
GSK-2245035 - Drug Profile 86
hdm-ASIT - Drug Profile 88
HX-100 - Drug Profile 89
Lactococcus lactis G121 - Drug Profile 91
Leukothera - Drug Profile 92
OC-000459 - Drug Profile 94
OC-2417 - Drug Profile 96
omalizumab biosimilar - Drug Profile 97
omalizumab biosimilar - Drug Profile 98
omalizumab biosimilar - Drug Profile 99
omalizumab biosimilar - Drug Profile 100
omalizumab biosimilar - Drug Profile 101
omalizumab biosimilar - Drug Profile 102
OND-86 - Drug Profile 103
pemirolast potassium - Drug Profile 104
pentosan polysulfate sodium - Drug Profile 105
PIN-201601 - Drug Profile 106
RPL-554 - Drug Profile 107
S-1226 - Drug Profile 110
SB-010 - Drug Profile 112
SG-100 - Drug Profile 114
SM-301 - Drug Profile 115
Small Molecule for Allergic Asthma - Drug Profile 116
Small Molecules for Allergic Asthma - Drug Profile 117
Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile 118
standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile 119
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile 121
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract - Drug Profile 123
SWE-01 - Drug Profile 125
tezepelumab - Drug Profile 126
Vaccine for Allergic Rhinitis and Allergic Asthma - Drug Profile 128
Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile 129
Allergic Asthma - Recent Pipeline Updates 130
Allergic Asthma - Dormant Projects 164
Allergic Asthma - Discontinued Products 168
Allergic Asthma - Product Development Milestones 169
Featured News & Press Releases 169
Appendix 177
Methodology 177
Coverage 177
Secondary Research 177
Primary Research 177
Expert Panel Validation 177
Contact Us 177
Disclaimer 178
List of Tables
Number of Products under Development for Allergic Asthma, H1 2016 13
Number of Products under Development for Allergic Asthma - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Development by Companies, H1 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H1 2016 24
Allergic Asthma - Pipeline by ALK-Abello A/S, H1 2016 25
Allergic Asthma - Pipeline by Allergopharma GmbH & Co. KG, H1 2016 26
Allergic Asthma - Pipeline by Amgen Inc., H1 2016 27
Allergic Asthma - Pipeline by Aquinox Pharmaceuticals Inc., H1 2016 28
Allergic Asthma - Pipeline by ASIT biotech s.a., H1 2016 29
Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016 30
Allergic Asthma - Pipeline by Axikin Pharmaceuticals, Inc., H1 2016 31
Allergic Asthma - Pipeline by Baxalta Incorporated, H1 2016 32
Allergic Asthma - Pipeline by Chiesi Farmaceutici SpA, H1 2016 33
Allergic Asthma - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 34
Allergic Asthma - Pipeline by CSL Limited, H1 2016 35
Allergic Asthma - Pipeline by Fountain Biopharma Inc., H1 2016 36
Allergic Asthma - Pipeline by GlaxoSmithKline Plc, H1 2016 37
Allergic Asthma - Pipeline by Hydra Biosciences, Inc., H1 2016 38
Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 39
Allergic Asthma - Pipeline by Kineta, Inc., H1 2016 40
Allergic Asthma - Pipeline by Mabtech Limited, H1 2016 41
Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H1 2016 42
Allergic Asthma - Pipeline by Mycenax Biotech Inc., H1 2016 43
Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H1 2016 44
Allergic Asthma - Pipeline by Oxagen Limited, H1 2016 45
Allergic Asthma - Pipeline by Panacea Biotec Limited, H1 2016 46
Allergic Asthma - Pipeline by Peptinnovate Limited, H1 2016 47
Allergic Asthma - Pipeline by Pharmaxis Limited, H1 2016 48
Allergic Asthma - Pipeline by Protectimmun GmbH, H1 2016 49
Allergic Asthma - Pipeline by Stallergenes SAS, H1 2016 50
Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016 51
Allergic Asthma - Pipeline by Swecure AB, H1 2016 52
Allergic Asthma - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 53
Allergic Asthma - Pipeline by Verona Pharma Plc, H1 2016 54
Assessment by Monotherapy Products, H1 2016 55
Assessment by Combination Products, H1 2016 56
Number of Products by Stage and Target, H1 2016 58
Number of Products by Stage and Mechanism of Action, H1 2016 61
Number of Products by Stage and Route of Administration, H1 2016 64
Number of Products by Stage and Molecule Type, H1 2016 66
Allergic Asthma Therapeutics - Recent Pipeline Updates, H1 2016 134
Allergic Asthma - Dormant Projects, H1 2016 168
Allergic Asthma - Dormant Projects (Contd..1), H1 2016 169
Allergic Asthma - Dormant Projects (Contd..2), H1 2016 170
Allergic Asthma - Dormant Projects (Contd..3), H1 2016 171
Allergic Asthma - Discontinued Products, H1 2016 172
List of Figures
Number of Products under Development for Allergic Asthma, H1 2016 13
Number of Products under Development for Allergic Asthma - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Products, H1 2016 20
Assessment by Monotherapy Products, H1 2016 55
Assessment by Combination Products, H1 2016 56
Number of Products by Top 10 Targets, H1 2016 57
Number of Products by Stage and Top 10 Targets, H1 2016 57
Number of Products by Top 10 Mechanism of Actions, H1 2016 60
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 60
Number of Products by Top 10 Routes of Administration, H1 2016 63
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 63
Number of Products by Top 10 Molecule Types, H1 2016 65
Number of Products by Stage and Top 10 Molecule Types, H1 2016 65
